Bengaluru-based Unimech Aerospace and Manufacturing and Ahmedabad-based Senores Pharmaceuticals have announced initial public offerings (Image credit: Social media)
Mumbai: Bengaluru-based Unimech Aerospace and Manufacturing and Ahmedabad-based Senores Pharmaceuticals have announced initial public offerings (IPOs) collectively worth over ₹1,000 crore, scheduled to open in the coming week.
Unimech Aerospace IPO Details
Unimech Aerospace has launched a ₹500 crore IPO in the price band of ₹745 to ₹785 per equity share with a face value of ₹5 each. The public offer will open on December 23, 2024, and close on December 26, 2024.
The IPO comprises a fresh issue of ₹250 crore and an offer for sale (OFS) of ₹250 crore. The proceeds from the fresh issue will fund capital expenditure for expansion, including the purchase of machinery and equipment, and provide for the company’s working capital requirements.
Unimech Aerospace IPO Details
Unimech Aerospace has launched a ₹500 crore IPO in the price band of ₹745 to ₹785 per equity share with a face value of ₹5 each. The public offer will open on December 23, 2024, and close on December 26, 2024.
The IPO comprises a fresh issue of ₹250 crore and an offer for sale (OFS) of ₹250 crore. The proceeds from the fresh issue will fund capital expenditure for expansion, including the purchase of machinery and equipment, and provide for the company’s working capital requirements.
Senores Pharmaceuticals IPO Details
Senores Pharmaceuticals has announced a ₹582 crore IPO with a price band of ₹372 to ₹391 per equity share with a face value of ₹10 each. The public offer opens on December 20, 2024, and closes on December 24, 2024.
The IPO includes a fresh issue of ₹500 crore and an OFS worth ₹82.11 crore. The proceeds from the fresh issue will be utilized for setting up a sterile injection manufacturing facility at the company’s Atlanta facility and for repayment of certain borrowings.
Senores Pharmaceuticals is a global research-driven pharmaceutical company specializing in the development and manufacturing of generic products for regulated markets like the US, Canada, and the UK, as well as emerging markets.
Both IPOs aim to strengthen the companies’ operational capacities and support their expansion strategies, presenting investment opportunities for market participants.
Senores Pharmaceuticals has announced a ₹582 crore IPO with a price band of ₹372 to ₹391 per equity share with a face value of ₹10 each. The public offer opens on December 20, 2024, and closes on December 24, 2024.
The IPO includes a fresh issue of ₹500 crore and an OFS worth ₹82.11 crore. The proceeds from the fresh issue will be utilized for setting up a sterile injection manufacturing facility at the company’s Atlanta facility and for repayment of certain borrowings.
Senores Pharmaceuticals is a global research-driven pharmaceutical company specializing in the development and manufacturing of generic products for regulated markets like the US, Canada, and the UK, as well as emerging markets.
Both IPOs aim to strengthen the companies’ operational capacities and support their expansion strategies, presenting investment opportunities for market participants.
( Source : Deccan Chronicle )
Next Story
